Cart
sales@molnova.com
CKD-519
CAS No. 1402796-27-3
CKD-519( Rocacetrapib | CKD519 )
Catalog No. M11682 CAS No. 1402796-27-3
CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 337 | Get Quote |
|
| 50MG | 1899 | Get Quote |
|
| 100MG | 2790 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCKD-519
-
NoteResearch use only, not for human use.
-
Brief DescriptionCKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM.
-
DescriptionCKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM; exhibites a maximum of 70%-86% inhibition of CETP activity and 25%-48% increase of HDL-C levels after two weeks of oral administration of 1, 3, or 10 mg/kg in transgenic mice expressing human CETP/apolipoprotein AI; CKD-519 (Rocacetrapib, CKD519) is being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol.Dyslipidemia Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsRocacetrapib | CKD519
-
PathwayMetabolic Enzyme/Protease
-
TargetCETP
-
RecptorCETP
-
Research AreaCardiovascular Disease
-
IndicationDyslipidemia
Chemical Information
-
CAS Number1402796-27-3
-
Formula Weight601.606
-
Molecular FormulaC31H34F7NO3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 66.67 mg/mL (110.82 mM)
-
SMILESC[C@H]1[C@@H](C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)OC(N1CC3=C(CCC(C)(C)C3)C4=C(OC)C=C(F)C(C(C)C)=C4)=O
-
Chemical Name(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5,5-dimethylcyclohex-1-en-1-yl}methyl)-4-methyl-1,3-oxazolidin-2-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kim CO, et al. Drug Des Devel Ther. 2016 Nov 15;10:3763-3770. eCollection 2016.
2. Lee S. Abstract 11228: a novel and potent CETP inhibitor, CKD-519 exerts strong HDL increment and anti-atherosclerotic effects. Circulation. 2013;128(Suppl 22):A11228.
molnova catalog
related products
-
Lomitapide Mesylate
Lomitapide Mesylate is a potent microsomal triglyceride transfer protein (MTP) inhibitor, used in the treatment of familial hypercholesterolemia.
-
Ro 5-3335
Ro 5-3335 is core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC50 = 1.1 μM).
-
Obicetrapib
Obicetrapib (AMG-899, TA-8995, DEX-001) is a potent, ora cholesteryl ester transfer protein (CETP) inhibitor for treatment of dyslipidaemia.
